carfilzomibi
Carfilzomib is a medication used to treat multiple myeloma, a type of blood cancer. It belongs to a class of drugs called proteasome inhibitors. Carfilzomib works by blocking the action of proteasomes, which are protein complexes within cells that break down unneeded or damaged proteins. In cancer cells, particularly myeloma cells, these proteasomes are crucial for survival and proliferation. By inhibiting proteasomes, carfilzomib disrupts the normal functioning of these cells, leading to their death.
Carfilzomib is typically administered intravenously. It is often used in combination with other medications, such as
Like all medications, carfilzomib can cause side effects. Common side effects may include fatigue, anemia, nausea,